key: cord-1009187-g8mrpiiv
authors: Berrichi, Samia; Bouayed, Zakaria; Benbouchta, Karima; Kossir, Amine; Bkiyar, Houssam; Ismaili, Nabila; Ouafi, Noha El; Housni, Brahim
title: Incidental diagnosis of a large cardiac thrombus swinging through an interatrial communication in a COVID-19 patient: Case report and literature review
date: 2021-10-19
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102967
sha: ff3f17a3feff9ec94410c07da8ccb24e03ebd085
doc_id: 1009187
cord_uid: g8mrpiiv

INTRODUCTION: The hypercoagulability state induced by COVID-19 has been well established and various forms of subsequent thromboembolic events have been reported throughout literature including multiple cases of intracardiac thrombi, four of which in our center alone, this case being the fifth. CASE REPORT: We report the case of a 38-year-old male with no prior cardiovascular history who -subsequently to a COVID-19 infection-developped a right atrial thrombosis associated to a pulmonary embolism, and in whom cardiography revealed an interatrial communication. Management relied upon curative doses of low molecular weight heparin (LMWH) with favourable outcome. DISCUSSION: In our discussion, we lay out the various physiopathological mechanisms incriminated throughout literature in the genesis of a hypercoagulability state distinctive of COVID-19, before highlighting the incidence of an interatrial communication (whether a Potent Foramen Ovale or Atrial Septal Defect) discovered in patients with COVID-19, and the potential paradoxical embolization risks they imply as well as reported cases. A mention of hemostatic parameters monitored was also warranted. Finally we discuss the guidelines in terms of prophylactic and therapeutic anticoagulation in hospitalized patients before discussing cardiac thrombosis's therapeutic options. CONCLUSION: Our case highlights various key points which could change the prognosis of COVID-19 patients, whether related to the underdiagnosis of interatrial abnormalities or with regards to the diagnosis to thromboembolic events, but also the indisputable place of anticoagulation in COVID-19 management.

Incidental diagnosis of a large cardiac thrombus swinging through an interatrial communication in a COVID-19 patient: case report and literature review

The hypercoagulability state induced by COVID-19 has been well established and various forms of subsequent thromboembolic events have been reported throughout literature including multiple cases of intracardiac thrombi, four of which in our center alone, this case being the fifth.

We report the case of a 38-year-old male with no prior cardiovascular history who -subsequently to a COVID-19 infection-developped a right atrial thrombosis associated to a pulmonary embolism, and in whom cardiography revealed an interatrial communication. Management relied upon curative doses of low molecular weight heparin (LMWH) with favourable outcome.

In our discussion, we lay out the various physiopathological mechanisms incriminated throughout literature in the genesis of a hypercoagulability state distinctive of COVID-19, before highlighting the incidence of an interatrial communication (whether a Potent Foramen Ovale or Atrial Septal Defect) discovered in patients with COVID-19, and the potential paradoxical embolization risks they imply as well as reported cases. A mention of hemostatic parameters monitored was also warranted. Finally we discuss the guidelines in terms of prophylactic and therapeutic anticoagulation in hospitalized patients before discussing cardiac thrombosis's therapeutic options.

After a year and half since the first cluster of COVID-19 cases have been reported in Wuhan, and now with more than 177 million cases worldwide confirmed to this day 1 and hundreds of cases published, it has become clear that COVID-19 is a complex multisystemic disease involving many organs and body systems 2 .

The thromboembolism events induced by COVID-19 and their consequences in terms of morbidiy and mortality have been well documented 3 , and are even greater when occuring in patients with an interatrial communication on account of the paradoxical embolization risks they entail.

Prophylactic anticoagulation has been recommended in all hospitalised patients admitted for management of COVID-19 specifically to lower the chances of thromboenbolic events and reduce their mortality 4 .

We report the case of a 38-year-old male with a COVID-19 infection and recent rapid worsening of an acute respiratory distress diagnosed with a pulmionay embolism and in whom cardiography revealed an interatrial communication, managed with curative doses of low molecular weight heparin (LMWH) with favourable outcome.

This paper has been reported in line with the SCARE 2020 criteria 5

A 38-year-old man with a history of schizophrenia under Haloperidol, Trihexyphenidyl, and Levomepromazine was admitted to the ER for the management of an acute respiratory distress, history of the present illness revealed that the patient first developed 2 weeks prior to his admission a flu-like syndrome made of fever, shivering, dry cough, myalgia, and shortness of breath on exertion for which the patient self-medicated without any improvement.

Following the rapid worsening of his dyspnea a day before, the patient sought the ER. On initial clinical assessment he was conscious and well oriented in time and space with a Glasgow Scale of 15/15, afebrile (36.8°C), tachycardic at a 140 beat per minute, normotensive at 125/75mmHg, with an O2 saturation of 84% on ambient air and 91% under nasal oxygen therapy (3L/min), pulmonary auscultation revealed right basal crackles.

An electrocardiogram (EKG) revealed a sinus rhythm with a high frequency of 140 beat per minute with an incomplete Right Bundle Branch Block (RBBB) and T wave inversion in V1 to V3 (figure 1).

Laboratory tests revealed a slightly elevated WBC (White Blood Count) of 11150/µL, a CRP (C Reactive Protein) level of 193,29 mg/L, with a hemoglobin at 11,1 g/dl, serum ferritin level of 1017,64 ng/mL, and LDH levels of 641 IU/L, HS Troponin levels at 115,2 ng/L, and an IL-6 level of 61 pg/mL, a platelet count of 239000, D-dimers levels at 3293 ng/mL, normal electrolyte, liver and kidney function tests. A SARS-Cov-2 RT-PCR of a nasal swap sample came back positive.

Initial arterial blood gas revealed: 7,54 pH, 116mmHg PaO2, 23mmHg PaCO2, 20mEq/l HCO3-, 2,29mmol/l lactatemia. A CXR showed ground-glass opacities (GGO) in the right lung (figure 2), Chest CT showed bilateral multifocal subpleural and peribronchial GGO (Glass Ground Opacities) with septal thickening and consolidation mainly in the periphery (figure 3), contrast-enhanced sequences revealed a filling defect in the left lobar pulmonary artery suggestive for pulmonary embolism (figure 4).

Considering the rapid worsening of the dyspnea, the EKG abnormalities and the pulmonary embolism we performed a transthoracic echocardiography (TTE) unveiling a large serpiginous floating thrombus (90 x 15mm) in the right and left atrium, straddling across an interatrial communication, and extending across the tricuspid and mitral valves, into the respective ventricles, the right heart cavities were dilated with paradoxical motion of the ventricular septum as well as a severe right ventricular systolic dysfunction with classic McConnell's sign and moderate pulmonary hypertension (pulmonary artery systolic pressure was estimated as 50 mmHg) ( Figures 5 and 6 ). Transesophageal echocardiography (TEE) was not performed given the patient's respiratory distress.

For the COVID-19 pneumonia the patient was treated with ceftriaxone 2g/day and levofloxacin 500mg/12h during ten days, dexamethasone 6mg/d, vitamins C 2g/12h and D 25000IU/week, zinc 45mg/day, and aspirin 160mg/day for the entire duration of hospitalization. As for the intra-cardiac thrombus and pulmonary embolism he received an 8000 IU subcutaneous injection of sodic enoxaparin every 12h also for the duration of his hospitalization.

A follow-up TTE was performed after 6 days revealing the total disappearance of the thrombus. Even though the patient exhibited no acute symptoms suggestive of a thromboembolic event a whole-body contrast-enhanced CT was performed as a precautionary measure and came back normal except for the pre-existing pulmonary embolism.

Follow-up laboratory tests showed a decrease of the inflammatory markers as well as D-dimers (from 3293 to 748 ng/mL).

Ther patient was gradually weaned off oxygen and discharged 14 days after admission, upon discharge we prescribed Apixaban 5mg/12h in concertation with our center's cardiology department which scheduled follow-up appointment for treatment adjustment and management of the interatrial communication.

The patient was seen 6 weeks later, a TTE was performed revealing a complete resolution of the pulmonary hypertension with normalization of the right heart cavities, completed by a TEE which showed no septal aneurysm, ASD, nor a PFO completed by a bubble test that was negative ( Figure 7 ).

In retrospect, we retained the diagnosis of a PFO re-opened by the right-heart high pressure secondary to the pulmonary embolism which progressed towards a functional closure of the PFO after normalization of the right atrial pressure.

Multiple cases of thromboembolic events related to COVID-19 have been reported, varying in terms of localisation (pulmonary, cardiac, peripheral arterial and/or venous), extension, gravity, and clinical features.

The high frequency of reported COVID-19 related thromboembolic events 6,7 raises the question of a unique physiopathology 8, 9 . Various intrigued pathological phenomena were incriminated 10 : from the cytokin storm 11 , passing by the complement cascade activation 12 , the macrophage activation 13 and antiphospholipid antibody 14 syndromes, to the the Renin angiotensin system overactivation 15 . All contributing to the genesis of a hypercoaguability state.

We report the case of a 38-year-old male with no cardiovacular risk factors other than his gender and no cardiovascular history who developped a COVID-19 pneumonia complicated shortly after with a large right intraatrial thrombus associated to a left lobar pulmonary artery, subsequently the patient's dyspnea worsened rapidly. The contrastenhanced CT revealed a pulmonary embolism while the TTE not only unveiled a large thrombus inside the right atrium but also an interatrial communication which exposed the patient to the risk of a paradoxical embolization, subsequently we anticoagulated with curative doses of low-molecular-weight heparin (LMWH). The non-visualisation of the thrombus on the follow-up TTE raised concerns of a paradoxical embolic event despite the absence of any clinical expression prompting us to perform a whole-body contrast-enhanced CT which came back normal.

The incidental discovery of an atrial septal abnormality should've pushed for a more comprehensive assessement 16 through multiple imaging technics such as a cardiography with agitated saline microbubbles test 17 or an electrocardiography-gated CT using the saline-chaser contrast injection technique 18 allowing to identify an interatrial shunt and to diffrentiate a patent foramen ovale (PFO) from an atrial septal defect (ASD).

In an Italian multi-center observational nationwide survey, Sabatino et al 19 of an under-diagnosis in patients with COVID-19 24 . As for paradoxial embolisms in patients with COVID-19, to our knowledge only 3 cases were reprted in the litterature [25] [26] [27] .

In a narrative review, Mondal et al 28 reported that venous thromboembolism and pulmonary embolism are respectively the most frequent forms of thromboembolic events related to COVID-19. As for intracardiac thrombosis, our case is the fifth reported within our center 29 , among a total of 630 COVID-19 patients admitted and managed since the beginning of the pandemic, joining only few cases reported in the litterature 30-37 , alternatively Rastogi et al 38 reported a total of 17 cardiac thrombi among a 1010 COVID-19 patients hospitalized within a one year timeline.

Various parameters were monitored in order to predict the severity of COVID-19 39,40 , impairement of hemostatic markers (especially elevated D-dimer and FDP) was widely observed in COVID-19 patients 41 , and even linked to a higher incidence of thromboembolic events 42 as well as an unfavourable prognosis 43 . In our case, a gradual decline of Ddimers levels (which were monitored daily since admission) was observed.

The International Society on Thrombosis and Hemostasis (ISTH) recommends the use of prophylactic doses of low molecular weight heparin (LMWH) in all patients (including non-critically ill) hospitalized for COVID-19 in the absence of any contraindications 4 which has been implimented in our center since the very beginning of the pandemic. Alongside its antucoagulant properties, Poterucha et al 44 layed out the various effects of hearin on inflammation pathaways, thus providing evidence of its anti-inflammatory properties.

The benefice of a curative anticoagulation in patients meeting certain criteria such as the sepsis-induced coagulopathy (SIC) score 45 has been proven, thus making the decision to initiate it much easier. Alternatively The American Society of Hematology (ASH) suggests using curative anticoagulation in patients who develop sudden clinical and laboratory findings consistent with pulmonary embolism, patients with physical findings consistent with thrombosis, and patients with respiratory failure, especially when D-dimer and/or fibrinogen levels are very high 46, 47 .

As for cardiac thrombosis, treatment options include anticoagulation, thrombolysis, and thrombectomy (surgical or percutaneous). Barrios et al 48 concluded that in patients with right heart thrombosis associated with pulmonary embolism, there is no significant difference between reperfusion therapy and anticoagulant therapy in terms of mortality and bleeding, in fact, a higher risk of recurrence for reperfusion therapy was reported in comparison with anticoagulation. In our case, the patient upon discussing treatment options opted for curative anticoagulation which led to the lysis of the thrombus.

Regarding limitations, as indicated above, a more comprehensive assessement using targeted imaging technics prevented a more precise diagnosis early-on.

Nonetheless, Follow-up led to a retrospective diagnosis of a functional closure of a PFO due to the resolution of the pulmonary embolism and subsequent normalization of right atrial pressure confirmed by cardiography.

COVID-19-related thromboembolic events are associated with a higher risk of mortality 3 , and are attributed to a a specific coagulopathy distinctive of to COVID-19 9 .

Our case's uniqueness resides in the unfortunate association of a right atrial embolism and an interatrial communication in a young patient with no cardiovadcular risk factors or history which underlines the likelihood of a significant underdiagnosis of atrial septal abonamalities especially given the high prevalence of PFO in the general population, and might account for a higher mortality in COVID-19 patients.

It also highlights the importance of contrast-enhanced imaging and cardiac evaluation in COVID-19 patients which may results in diagnosing more thromboembolic events and subsequent adequate management.

This paper has been reported in line with the SCARE 2020 criteria 5 J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

We have no conflicts of interest

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

This work hasn't received any funding

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

This is a case report , therefore Ethics committee/IRB approval is not required.

J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorin-Chief of this journal on request

COVID-19) Dashboard

COVID-19: a complex multisystem disorder

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29-30:100639

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

COVID-19 and its implications for thrombosis and anticoagulation

COVID-19 Related Coagulopathy: A Distinct Entity?

Thrombosis in COVID-19

The looming storm: Blood and cytokines in COVID-19

Crosstalk between the coagulation and complement systems in sepsis

COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?

Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots

COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight? Med Hypotheses

Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions

Protocol for optimal detection and exclusion of a patent foramen ovale using transthoracic echocardiography with agitated saline microbubbles

Interatrial shunt: diagnosis of patent foramen ovale and atrial septal defect with 64-row coronary computed tomography angiography

COVID-19 and Congenital Heart Disease: Results from a Nationwide Survey

Patent foramen ovale revealed by COVID-19 pneumonia

Acute Stroke in a Young Patient With Coronavirus Disease 2019 in the Presence of Patent Foramen Ovale

Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset

Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review

Systemic thromboemboli in patients with Covid-19 may result from paradoxical embolization

Middle cerebral artery stroke due to paradoxical embolism in a patient with COVID-19 pneumonia

Paradoxical Embolism Causing Myocardial Infarction in a COVID-19

Thromboembolic disease in COVID-19 patients: A brief narrative review

Intra cardiac thrombus in critically ill patient with coronavirus disease 2019: Case report

Bi-atrial thrombosis in a patient with SARS-CoV-2 infection: a case report

A case report of a large intracardiac thrombus in a COVID-19 patient managed with percutaneous thrombectomy and right ventricular mechanical circulatory support

Large intracardiac thrombus in a COVID-19 patient treated with prolonged extracorporeal membrane oxygenation implantation

COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis

Giant intracardiac thrombosis in an infant with leukaemia and prolonged COVID-19 viral RNA shedding: a case report

Multiple Intracardiac Thrombi Complicated by Pulmonary Embolism

Unusual intracardiac thrombosis in two patients with coronavirus disease 2019 (COVID-19): case series

Right Atrial Thrombus in a COVID-19 Child Treated Through Cardiac Surgery

PREDICTORS OF COVID-19 RELATED INTRA-CARDIAC THROMBUS FROM ADMISSION LABORATORY VALUES

The value of clinical parameters in predicting the severity of COVID-19

Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

More than an anticoagulant: Do heparins have direct anti-inflammatory effects?

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. 

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry:

Unique Identifying number or registration ID:3.Hyperlink to your specific registration (must be publicly accessible and will be checked):

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish